Shares of Aileron Therapeutics Inc (NASDAQ:ALRN) have received a consensus broker rating score of 1.00 (Strong Buy) from the four analysts that provide coverage for the stock, Zacks Investment Research reports. Four research analysts have rated the stock with a strong buy recommendation.
Brokerages have set a 12 month consensus price objective of $19.33 for the company and are forecasting that the company will post ($0.46) earnings per share for the current quarter, according to Zacks. Zacks has also assigned Aileron Therapeutics an industry rank of 179 out of 265 based on the ratings given to related companies.
Separately, Zacks Investment Research upgraded shares of Aileron Therapeutics from a “sell” rating to a “hold” rating in a research report on Wednesday, January 10th.
Aileron Therapeutics (NASDAQ:ALRN) last announced its quarterly earnings data on Thursday, November 9th. The company reported ($0.43) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.36) by ($0.07). analysts predict that Aileron Therapeutics will post -1.76 earnings per share for the current year.
In other news, major shareholder Apple Tree Partners Ii Lp sold 150,000 shares of the firm’s stock in a transaction on Tuesday, January 9th. The shares were sold at an average price of $9.80, for a total transaction of $1,470,000.00. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. 68.10% of the stock is owned by company insiders.
A number of hedge funds and other institutional investors have recently made changes to their positions in the business. California State Teachers Retirement System bought a new stake in Aileron Therapeutics in the 3rd quarter valued at $110,000. Schwab Charles Investment Management Inc. bought a new stake in Aileron Therapeutics in the 3rd quarter valued at $165,000. Bank of New York Mellon Corp bought a new stake in Aileron Therapeutics in the 3rd quarter valued at $135,000. Nexthera Capital LP bought a new stake in Aileron Therapeutics in the 2nd quarter valued at $1,272,000. Finally, Goldman Sachs Group Inc. bought a new stake in Aileron Therapeutics in the 2nd quarter valued at $418,000. Institutional investors own 7.64% of the company’s stock.
ILLEGAL ACTIVITY WARNING: “Zacks: Brokerages Set $19.33 Target Price for Aileron Therapeutics Inc (ALRN)” was published by Chaffey Breeze and is the sole property of of Chaffey Breeze. If you are reading this piece on another website, it was illegally stolen and reposted in violation of United States & international copyright and trademark law. The correct version of this piece can be viewed at https://www.chaffeybreeze.com/2018/01/20/zacks-brokerages-set-19-33-target-price-for-aileron-therapeutics-inc-alrn.html.
Aileron Therapeutics Company Profile
Aileron Therapeutics, Inc is a United States-based clinical-stage biopharmaceutical company. The Company is focused on developing and commercializing a class of therapeutics called stapled peptides. It is also developing a pipeline of stapled peptide drugs across a range of therapeutic areas, including cancer, endocrine and metabolic diseases and inflammation.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Aileron Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aileron Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.